These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30028993)

  • 21. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins.
    Schreiber KH; Ortiz D; Academia EC; Anies AC; Liao CY; Kennedy BK
    Aging Cell; 2015 Apr; 14(2):265-73. PubMed ID: 25652038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
    Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
    Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTORC1 and mTORC2 are differentially engaged in the development of laser-induced CNV.
    Yang JY; Madrakhimov SB; Ahn DH; Chang HS; Jung SJ; Nah SK; Park HY; Park TK
    Cell Commun Signal; 2019 Jun; 17(1):64. PubMed ID: 31200728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
    Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M
    Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
    Sini P; James D; Chresta C; Guichard S
    Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy.
    Talos DM; Jacobs LM; Gourmaud S; Coto CA; Sun H; Lim KC; Lucas TH; Davis KA; Martinez-Lage M; Jensen FE
    Ann Neurol; 2018 Feb; 83(2):311-327. PubMed ID: 29331082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTORC1 and mTORC2 regulate skin morphogenesis and epidermal barrier formation.
    Ding X; Bloch W; Iden S; Rüegg MA; Hall MN; Leptin M; Partridge L; Eming SA
    Nat Commun; 2016 Oct; 7():13226. PubMed ID: 27807348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
    Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
    Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons.
    Kim SG; Lee S; Kim Y; Park J; Woo D; Kim D; Li Y; Shin W; Kang H; Yook C; Lee M; Kim K; Roh JD; Ryu J; Jung H; Um SM; Yang E; Kim H; Han J; Heo WD; Kim E
    Nat Commun; 2021 May; 12(1):2695. PubMed ID: 33976205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Novel mTOR Complex 1/2 Inhibitor P529 Inhibits Human Lung Myofibroblast Differentiation.
    Ferguson KT; Torr EE; Bernau K; Leet J; Sherris D; Sandbo N
    J Cell Biochem; 2017 Aug; 118(8):2241-2249. PubMed ID: 28078713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
    Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assembly of mTORC3 Involves Binding of ETV7 to Two Separate Sequences in the mTOR Kinase Domain.
    Zhan J; Harwood F; Have ST; Lamond A; Phillips AH; Kriwacki RW; Halder P; Cardone M; Grosveld GC
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
    Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential therapeutic effects of mTOR inhibition in atherosclerosis.
    Kurdi A; De Meyer GR; Martinet W
    Br J Clin Pharmacol; 2016 Nov; 82(5):1267-1279. PubMed ID: 26551391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.
    Bracho-Valdés I; Moreno-Alvarez P; Valencia-Martínez I; Robles-Molina E; Chávez-Vargas L; Vázquez-Prado J
    IUBMB Life; 2011 Oct; 63(10):896-914. PubMed ID: 21905202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
    Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
    PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next Generation Strategies for Geroprotection via mTORC1 Inhibition.
    Dumas SN; Lamming DW
    J Gerontol A Biol Sci Med Sci; 2020 Jan; 75(1):14-23. PubMed ID: 30794726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct imaging of the recruitment and phosphorylation of S6K1 in the mTORC1 pathway in living cells.
    Ahmed AR; Owens RJ; Stubbs CD; Parker AW; Hitchman R; Yadav RB; Dumoux M; Hawes C; Botchway SW
    Sci Rep; 2019 Mar; 9(1):3408. PubMed ID: 30833605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
    Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
    Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.